Approval · Notice of Compliance 29705 · 2022
KYNMOBI: Notice of Compliance 29705
Issued December 15, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29705
- Date
- December 15, 2022
- Company
- Sunovion Pharmaceuticals Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Updates to the Product Monograph (PM), conversion to the PM Master Template and review of the package insert (PI).
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KYNMOBI | Not yet assigned | — |
Medicinal ingredients
- APOMORPHINE HCL 10 MG per UNIT
- APOMORPHINE HCL 15 MG per UNIT
- APOMORPHINE HCL 20 MG per UNIT
- APOMORPHINE HCL 25 MG per UNIT
- APOMORPHINE HCL 30 MG per UNIT